by emma
19. September 2011 10:46
Orexo AB has appointed Nikolaj Sørensen as its new Chief Commercial Officer.
He will be responsible for commercial operations, as well as development of the company’s commercial strategies, and brings a wealth of international commercial experience.
Anders Lundström, President and CEO of Orexo AB, says the company is “particularly pleased” to recruit Mr Sørensen whose “background suits the company’s strategy”.
Mr Sørensen has previously worked at Pfizer where he was a Director and Brand Team Leader for pain treatment product in Europe and Canada. He also worked as Head of Business Development and Director of Strategic Planning, plus Business Area Director for primary care products, and as Managing Director and Chairman of the board for Pfizer AB.
For the past few years, he has also been a member of the Board of the Swedish Pharmaceutical Industry Association (LIF).
The company currently has four commercialised products and several projects developed in partnership, plus three further proprietary development programs. Its new Chief Commercial Officer says he has followed the progress of the company for a number of years.
“Orexo is an exciting company that I have followed for several years,” said Mr Sørensen. “The company has a very interesting product portfolio that provides a solid foundation for a commercial organisation. I look forward to developing and executing Orexo’s strategy for sales and marketing of the company’s own products.”
He will commence his role on 1 October.
8bb59626-3579-4dd9-81d9-d0f8b7b3f510|0|.0
Tags: Orexo, CCO, AB, Nikolaj Sorensen, Chief Commercial Officer, development, company, business, industry, sector, Anders Lundstrom, President, CEO, strategies, international, Pfizer, Director, Brand Team Leader, pain treatment, product, Europe, Canada, primary care, appointment, vacancy, job, medical sales, pharma, drug, pharmaceutical, post, position, role, career, marketing, organisation
Appointments
Subscribe